Journal of Neuro-Oncology

, Volume 115, Issue 3, pp 445–452 | Cite as

Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa

  • A. Comte
  • W. Jdid
  • M. N. Guilhaume
  • I. Kriegel
  • S. Piperno-Neumann
  • V. Dieras
  • T. Dorval
  • J. Y. Pierga
  • P. H. Cottu
  • L. Mignot
  • F. C. Bidard
Clinical Study

Abstract

Treatment of breast cancer meningeal carcinomatosis (MC) relies on intrathecal chemotherapy. Thiotepa is one of the few drugs approved in this setting, although no large cohort has been reported. The aim of our retrospective study is to describe survival and prognostic factors of breast cancer patients treated by intrathecal thiotepa. A search in the electronic database of the Institut Curie was performed and retrieved the patients diagnosed with breast cancer MC from 2000 to 2012 and who received at least one intrathecal injection of thiotepa. The standard regimen was intrathecal thiotepa (10 mg) and methylprednisolone (40 mg), repeated every other week. Clinical data were retrieved from the computerized medical file of each patient. Sixty-six patients have been treated with intrathecal thiotepa either as first line or second line of treatment for breast cancer MC. The median overall survival was 4.5 months (range 0.1–50). There was no significant survival difference between patients treated as first or second line. In multivariate analysis, main adverse prognostic factors at diagnosis were performance status >2 (p = 0.001, RR = 3.4, 95 % CI 1.6–7.2) and history of more than 3 previous systemic chemotherapy lines (p = 0.002, RR = 2.90, 95 % CI 1.50–5.65). After start of the treatment, high primary tumor grade, elevated Cyfra 21-1 levels in the cerebrospinal fluid, and lack of clinical improvement were also independent adverse prognostic factors in multivariate analysis. This is the largest retrospective cohort of breast cancer MC treated by intrathecal thiotepa ever reported. The median overall survival was short but some patients clearly benefited from this treatment, even used as second line.

Keywords

Breast cancer Meningeal carcinomatosis Neoplastic meningitis Thiotepa 

References

  1. 1.
    DeAngelis LM (1998) Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 38(2–3):245–252PubMedCrossRefGoogle Scholar
  2. 2.
    Chamberlain MC (2008) Neoplastic meningitis. Oncologist 13(9):967–977PubMedCrossRefGoogle Scholar
  3. 3.
    Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49(4):759–772PubMedCrossRefGoogle Scholar
  4. 4.
    Van Horn A, Chamberlain MC (2012) Neoplastic meningitis. J Support Oncol 10(2):45–53PubMedCrossRefGoogle Scholar
  5. 5.
    Beauchesne P (2010) Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 11(9):871–879PubMedCrossRefGoogle Scholar
  6. 6.
    Shapiro WR, Johanson CE, Boogerd W (2009) Treatment modalities for leptomeningeal metastases. Semin Oncol 36(4 Suppl 2):S46–S54PubMedCrossRefGoogle Scholar
  7. 7.
    Hitchins RN, Bell DR, Woods RL, Levi JA (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5(10):1655–1662PubMedGoogle Scholar
  8. 8.
    Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394–3402PubMedGoogle Scholar
  9. 9.
    Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR (1982) Treatment for meningeal carcinomatosis in breast cancer. Cancer 50(2):219–222PubMedCrossRefGoogle Scholar
  10. 10.
    Ongerboer de Visser BW, Somers R, Nooyen WH, van Heerde P, Hart AA, McVie JG (1983) Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33(12):1565–1572PubMedCrossRefGoogle Scholar
  11. 11.
    Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T, Pouillart P (1996) Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 77(7):1315–1323PubMedCrossRefGoogle Scholar
  12. 12.
    Chamberlain MC (2012) Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol 109(1):143–148Google Scholar
  13. 13.
    Bleyer WA, Drake JC, Chabner BA (1973) Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289(15):770–773PubMedCrossRefGoogle Scholar
  14. 14.
    Gutin PH, Levi JA, Wiernik PH, Walker MD (1977) Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 61(5):885–887PubMedGoogle Scholar
  15. 15.
    Gutin PH, Weiss HD, Wiernik PH, Walker MD (1976) Intrathecal N,N′,N-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study. Cancer 38(4):1471–1475PubMedCrossRefGoogle Scholar
  16. 16.
    Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11(3):561–569PubMedGoogle Scholar
  17. 17.
    Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Dieras V (2010) Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 21(11):2183–2187PubMedCrossRefGoogle Scholar
  18. 18.
    Giannone L, Greco FA, Hainsworth JD (1986) Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 4(1):68–73PubMedGoogle Scholar
  19. 19.
    Bidard FC, Lossignol D, Larsimont D, Piccart M, Awada A (2011) Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis. Ann Oncol 22(2):480–482PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • A. Comte
    • 1
  • W. Jdid
    • 1
  • M. N. Guilhaume
    • 1
  • I. Kriegel
    • 2
  • S. Piperno-Neumann
    • 1
  • V. Dieras
    • 1
  • T. Dorval
    • 1
  • J. Y. Pierga
    • 1
    • 3
  • P. H. Cottu
    • 1
  • L. Mignot
    • 1
  • F. C. Bidard
    • 1
    • 4
  1. 1.Department of Medical OncologyInstitut CurieParisFrance
  2. 2.Department of AnesthesiaInstitut CurieParisFrance
  3. 3.University Paris DescartesParisFrance
  4. 4.Breast Cancer Molecular PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations